INTEGRATED BIOPHARMA INC
INTEGRATED BIOPHARMA INC (INBP): 2 pipeline candidates · 1 upcoming catalyst · ~35 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
35.1 months
D/E 0.41 · 0% dilution
N/A
2 candidates
1 upcoming, next in ~75d
N/A
A transparent, data-derived signal for INTEGRATED BIOPHARMA INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.9M
Cash
$5.8M
Quarterly Burn
$809K
Runway
35.1 mo
Revenue
$10.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| deka arm system | — |
| deka arm system | — |
Upcoming Catalysts (1)
Frequently asked questions
How many drug candidates are in INTEGRATED BIOPHARMA INC's pipeline?
INTEGRATED BIOPHARMA INC (INBP) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is INTEGRATED BIOPHARMA INC's next catalyst?
INTEGRATED BIOPHARMA INC's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients Wi" — expected September 1, 2026.
What is INTEGRATED BIOPHARMA INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, INTEGRATED BIOPHARMA INC has approximately 35.1 months of cash runway.
What is INTEGRATED BIOPHARMA INC's market capitalization?
INTEGRATED BIOPHARMA INC's market capitalization is approximately $5.9M.
Who is the CEO of INTEGRATED BIOPHARMA INC?
Ms. Riva Kay Sheppard is the chief executive officer of INTEGRATED BIOPHARMA INC (INBP).
Get the full picture on INTEGRATED BIOPHARMA INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.